Initial clinical studies with 5-iodo-2'-deoxyuridine.

Peter A. Calabresi, Cardoso Ss, Finch Sc, Kligerman Mm, von Essen Cf, My Chu, Welch AdPubMed 1961

Abstract

Summary The results of preliminary clinical pharmacological investigations of 5-iodo-2′-deoxyuridine (IUDR), an analog of thymidine, are reported. With dosages of 100–120 mg IUDR/kg, infused intravenously during periods of 2–3 hours daily for 5 or 6 days, studies of the urinary excretion of IUDR, 5-iodouracil, and iodide indicated that significant blood levels of IUDR were maintained for approximately 4 hours. The major toxic effects of such dosage regimens were stomatitis, leukopenia, and alopecia. In the present series, evidence of modest tumor inhibition was observed in six of sixteen patients with advanced neoplastic disease. Possible areas for future investigations with this compound, particularly in combination with other antimetabolites and radiation therapy, have been discussed.
BibTeX
@inproceedings{calabresi1961initial,
  author = {Peter A. Calabresi and Cardoso Ss and Finch Sc and Kligerman Mm and von Essen Cf and My Chu and Welch Ad},
  title = {{Initial clinical studies with 5-iodo-2'-deoxyuridine.}},
  booktitle = {PubMed},
  year = {1961},
}

Loading related content...

Figure